Figure 2. Meta-analysis of the association between GALNT6 overexpression and OS in breast cancer studies in the SurvExpress datasets. Eight published breast cancer studies were included for overall survival analysis. The OS pooled HR 95% CI of GALNT6 was 0.24 (0.05; 0.43) and 0.23 (0.01; 0.45) in the fixed and random effects model analyses, respectively. TE, treatment effect; seTE, standard error of TE. The dashed line on the graph represents the HR of the aggregated results. It shows the position of the meta-analysis results in each independent study.